Navigation Links
New Test Helps Identify Hepatitis C Patients at High Risk of Developing Cirrhosis

own as cirrhosis, which in turn may result in liver cancer or liver failure. Hepatitis C infection is the most common reason people need a liver transplant in the United States and is responsible for between 8,000 and 10,000 U.S. deaths annually.

But in the majority of people chronically infected with hepatitis C, the virus causes either no symptoms or vague, nonspecific ones. In around one-third of people chronically infected with the virus, the disease progression is slow and they may never develop cirrhosis, even after decades of infection.

The dilemma physicians face, explained Cheung, is deciding who to treat and who can wait for better therapies to come along. The key is being able to determine which patients are likely to see the infection progress to cirrhosis. Doctors consider such factors as age, gender and alcohol consumption to predict such risk, but because of individual variability, these factors don't yield a very accurate prediction. A liver biopsy can indicate the amount of damage to the liver up until the time of the biopsy, but can't reveal how much future damage will occur.

The new test assessed by Cheung and his colleagues is a way to hedge the bets.

The lead author of the paper is Hongjin Huang, PhD, associate director of liver diseases at Celera in Alameda, Calif. Huang and her Celera colleagues developed the test by initially scanning the DNA of more than 1,000 people who had hepatitis C. Out of 25,000 genetic variations tested, the researchers discovered seven that could be used together as a "signature" for predicting progression to cirrhosis in Caucasians.

The resulting gene signature - the Cirrhosis Risk Score - was then independently validated on 154 hepatitis C patients at Stanford, the University of Illinois-Chicago and California Pacific Medical Center. Among patients with early-stage liver disease, the researchers were able to divide them into a high-risk category based on t
'"/>




Page: 1 2 3

Related medicine news :

1. Antibiotics Helps Autism
2. Serum Progesterone Helps Stratify Ectopic Pregnancy Risk
3. Prescription Drug - Helps People Stop Smoking
4. New Drug PP188 Helps Sickle Cell Disease
5. Red Wine Helps Fight Heart disease
6. Creatine Helps Strengthen Older Men
7. Cholesterol Drug Helps After Angioplasty
8. Virus Helps Remove Brain Cancer
9. Eating Fish Helps the Heart
10. Antidepressant Helps Relieve Hot Flashes
11. Epilepsy Drug Helps Diabetic Nerve Damage
Post Your Comments:
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Begin...l/ -- Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ...ced today that its subsidiary has commenced commer...psules USP product in the 40mg,strength from its D...on,with the launch, Watson has 180 days of marketi...
(Date:7/25/2008)...AUMBURG, Ill., July 25 /PRNewswire/ -- Sagent Phar...maceutical company, today announced that it,has la...antiarrhythmic,indicated for the treatment and pro...llation and hemodynamically unstable ventricular,t...ular heart beat.,Sagent,s amiodarone HCl injection...
(Date:7/25/2008)...LSBAD, Calif., July 25 /PRNewswire/ -- AutoGenomic...ration statement on Form S-1 with the,Securities a...itial public,offering of shares of its common stoc...red, all of which are expected to be offered by,Au...ring, have not yet been,determined., J.P. Morgan ...
(Date:7/25/2008)... New program delivers immediate ... [24-hour telephone access to language interprete...ing multilingual solutions. , ... LLE® http://www.lle-inc.com/index.html [(L...ovider of interpretation, translation, and languag...
Breaking Medicine News(10 mins):Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 3
...ide a bridge to a transplant.Heart failure is char...le to pump blood around the body. Till now, it has...sible - with the only real cure being a transplant...e (LVAD) is a mechanical pump which is used to sup...
...lly to the heart.Improvements in heart disease ris...smoking. It's known that smoking increases the ris...oxide in cigarette smoke,// which raises cholester...ther heart disease risk factors. Each 1% increase ...
...e more likely to have a specific variant of a bloo... tests on 500 men who had died suddenly, many of w... men younger than 55, a gene variant known as HPA-... common than in the general population.// The gen...
...skin could be better than white at fending off fun... James Mackintosh says it could explain why dark s...al environments. A popular theory on why darker sk... skin in others, is that// the extra melanin in da...
Other Medicine News:
(Date:7/23/2008)...TTLE, July 23 /- Sound Pharmaceutical...ication with the FDA for the clinical,testing of a...tion of,chemotherapy induced hearing loss or ototo...005, will be tested in advanced stage lung cancer,...um based chemotherapy.,This marks the second devel...
(Date:7/23/2008)...TTLE, July 23 /- Dendreon C...t expects the Independent Data,Monitoring Committe...lysis,of overall survival relating to the Company,...Carcinoma Treatment, also known as D9902B) clinica... the Company,s investigational,active cellular imm...
(Date:7/22/2008)...est awards under Therapeutics Development Initiati...ions to 23; next deadline January 20,2009, NEW Y... its mission to,speed delivery of transformative t...Michael J. Fox Foundation for Parkinson,s Research...industry research teams. The awards,were granted u...
(Date:7/22/2008)...Geoffrey Allan Will Stress the Importance to Patie...ics Approval Pathway, RICHMOND, Va., July 22 /PRN...) a developer of follow-on biologics and biopharma....D., CEO of Insmed, will present at a,Congressiona...he,significant need for establishing an approval p...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD 385 1Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD 385 2Adult offspring of parents with PTSD have lower cortisol levels 381 1Adult offspring of parents with PTSD have lower cortisol levels 381 24 Star Gen Barry McCaffrey Former U S Drug Czar to Address National Drug Crisis Keynote Grand Opening of New Allenwood PA National Model Detox C 377 14 Star Gen Barry McCaffrey Former U S Drug Czar to Address National Drug Crisis Keynote Grand Opening of New Allenwood PA National Model Detox C 377 2American Chemical Societys Weekly Presspac Aug 29 2007 218 1American Chemical Societys Weekly Presspac Aug 29 2007 218 2American Chemical Societys Weekly Presspac Aug 29 2007 218 3American Chemical Societys Weekly Presspac Aug 29 2007 218 4American Chemical Societys Weekly Presspac Aug 29 2007 218 5American Chemical Societys Weekly Presspac Aug 29 2007 218 6American Chemical Societys Weekly Presspac Aug 29 2007 218 7American Chemical Societys Weekly Presspac Aug 29 2007 218 8
...NA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 - Caland...mpany and a,majority-owned subsidiary of Arrowhead... publication in the Proceedings of the,National Ac...f the,NAS, of the first non-human primate study to... siRNA therapeutic candidate that is a,nanoparticl...
...FIELD, N.J., March 20, 2007 /PRNewswire-FirstCall/...as shown potential to,act as a potent payload in a...o the latest edition of the Handbook of Therapeuti...ews immunotoxins, Susanna,Rybak, Ph.D. summarizes ...ty and potency of ONCONASE improves in a number of...
Other Medicine Technology:Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 2Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 3Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 4Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 5Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 2Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 3Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 4
The NOW® Malaria Test is a field or laboratory test for the differential diagnosis of a Malaria infection. It is intended for the detection of circulating Plasmodium falciparum (P.f.) antigen
Ultraview 1700 Central Monitor
...tient Care Monitor (PCM) and Central Station provi...PCM extends the cardiac cath or electrophysiology ...ath and/or EP procedures, providing both physiomon...device either standalone or on its own network. W...
...nitoring via the Acuity central station and Welch ...nvert non-monitored beds into centrally monitored ...t both wireless and hardwired monitors and clinica...ities from a community hospital to a teaching inst...
Medicine Products: